Inventiva (IVA) Non-Current Deffered Revenue (2018 - 2025)
Inventiva (IVA) posted quarterly Non-Current Deffered Revenue of $146669.5 for Q4 2025, up 28.28% year-over-year from $114339.7 in Q4 2024, and down 99.9% quarter-over-quarter from $142.6 million in Q2 2025.
Analysis
Inventiva (IVA) Non-Current Deffered Revenue (2018 - 2025) Analysis & Trends
Inventiva's Non-Current Deffered Revenue history runs 5 years deep, the most recent figure standing at $146669.5 for Q4 2025.
- In Q4 2025, Non-Current Deffered Revenue rose 28.28% year-over-year to $146669.5; the TTM figure through Dec 2025 stood at $146669.5 (up 28.28% YoY), while the FY2025 annual figure was $146669.5, up 28.28% from the prior year.
- Non-Current Deffered Revenue for Q4 2025 stood at $146669.5, down from $142.6 million in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $142.6 million in Q2 2025, with the low at $56113.6 in Q4 2022.
- The 4-year median for Non-Current Deffered Revenue is $81843.5 (2024), against an average of $20.5 million.
- The sharpest annual moves came in 2024 and 2025: Non-Current Deffered Revenue grew 23.21% in 2024, then soared 174167.96% in 2025.
- Inventiva's Non-Current Deffered Revenue stood at $56113.6 in 2022, then soared by 34.22% to $75315.8 in 2023, then jumped by 51.81% to $114339.7 in 2024, then rose by 28.28% to $146669.5 in 2025.
- Business Quant data shows IVA's Non-Current Deffered Revenue at $146669.5 in Q4 2025, $142.6 million in Q2 2025, and $114339.7 in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 147.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Inventiva | 893.85 Mn | 893.85 Mn | - | 146,669.48 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 146,669.48 |
| Jun 30, 2025 | 142,626.92 |
| Dec 31, 2024 | 114,339.71 |
| Dec 31, 2023 | 75,315.79 |
| Jun 30, 2023 | 66,424.39 |
| Dec 31, 2022 | 56,113.61 |
| Dec 31, 2018 | 1.91 Mn |